Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Depreciation and Depletion (2017 - 2019)

Historic Depreciation and Depletion for Arrowhead Pharmaceuticals (ARWR) over the last 3 years, with Q2 2019 value amounting to $578342.0.

  • Arrowhead Pharmaceuticals' Depreciation and Depletion fell 2300.42% to $578342.0 in Q2 2019 from the same period last year, while for Jun 2019 it was $2.9 million, marking a year-over-year change of. This contributed to the annual value of $3.0 million for FY2018, which is 29.55% up from last year.
  • According to the latest figures from Q2 2019, Arrowhead Pharmaceuticals' Depreciation and Depletion is $578342.0, which was down 2300.42% from $750860.0 recorded in Q1 2019.
  • In the past 5 years, Arrowhead Pharmaceuticals' Depreciation and Depletion ranged from a high of $803288.0 in Q3 2018 and a low of $578342.0 during Q2 2019
  • For the 3-year period, Arrowhead Pharmaceuticals' Depreciation and Depletion averaged around $725756.3, with its median value being $750860.0 (2019).
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Depreciation and Depletion skyrocketed by 505.25% in 2018, and later plummeted by 2300.42% in 2019.
  • Arrowhead Pharmaceuticals' Depreciation and Depletion (Quarter) stood at $716066.0 in 2017, then grew by 5.05% to $752245.0 in 2018, then fell by 23.12% to $578342.0 in 2019.
  • Its last three reported values are $578342.0 in Q2 2019, $750860.0 for Q1 2019, and $752245.0 during Q4 2018.